Manufacturing
Page 1 • 8 itemsGlobal pharma manufacturing insights: Track supply chain, CMC, regulatory compliance, and innovation trends impacting drug production. Stay ahead.
Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing
South Korean biotech Novelty Nobility expands manufacturing deal with AGC Biologics to advance bispecific antibody candidate through GMP production in Japan.
Pharmaceutical Manufacturing Software Market to Reach $7.87 Billion by 2030, Driven by 15.8% CAGR Growth
Pharmaceutical manufacturing software market grows from $3.82B to $4.43B in 2026 with 15.8% CAGR, projected to reach $7.87B by 2030 amid regulatory demands.
Small Molecule API Market Projected to Reach $202.53 Billion by 2036 as Generic Drug Demand Surges
Small molecule API market set to hit $202.53 billion by 2036, driven by generic drug demand and oncology pipeline expansion across global markets.
Pharmaceutical Isolators Market Reaches $7.82 Billion as EU GMP Annex 1 Drives Manufacturing Safety Requirements
The global pharmaceutical isolators market hits $7.82 billion, driven by EU GMP Annex 1 regulations and rising HPAPI production demands through 2031.
Mabwell Achieves First PIC/S GMP Compliance Certification from Jordan FDA for Biopharmaceutical Manufacturing
Mabwell's T-mab subsidiary passes Jordan FDA GMP inspection, marking first PIC/S regulatory compliance for the Chinese biopharmaceutical company's manufacturing.
Continuous Manufacturing in Pharmaceuticals: EU Regulatory Insights & Innovation
Discover how continuous manufacturing is transforming pharmaceutical production, with key EU regulatory insights and innovations for drug safety and efficiency.
CMO/CDMO Market to Reach $5.46 Billion by 2035 as Biologics Manufacturing Outsourcing Accelerates
The global CMO/CDMO market will grow from $4.02 billion to $5.46 billion by 2035, driven by biologics outsourcing and specialized manufacturing demand.
EU Pharmaceutical Strategy: Impact on API Manufacturing in Europe
The EU Pharmaceutical Strategy aims to strengthen API manufacturing in Europe, ensuring a stable supply of essential drugs for chronic disease management.